Saturday, 31 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Regulatory Approval

Auro Laboratories Regulatory Approval

Auro Laboratories Ltd has received a Certificate of GMP Compliance (No. 26-0002) from Swissmedic for its manufacturing facility in Tarapur, Maharashtra. The certification confirms compliance with GMP requirements under the EU-Switzerland Mutual Recognition Agreement, validating the plant's quality standards for therapeutic products.

Source

BSE filing, NSE: AUROLAB. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Auro Laboratories Ltd: key numbers

Share price
₹232.75
Market cap
₹145.1 Cr
Revenue (annual)
₹32.61 Cr
Net profit (annual)
₹3.53 Cr
P/E (TTM)
31.0×Sector 45.9×
Promoter holding
52.40%+0.00% QoQ
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Auro Laboratories Ltd

All →

Other regulatory approval announcements

All →
21:58 IST BSE
Regulatory ApprovalNesco Ltd NESCO

Nesco Regulatory Approval

Nesco Limited received a Commencement Certificate from BMC for Tower-2 and Hall-1 at Nesco Center, Goregaon. The company can now proceed with construction and development of the proposed projects, valid until 29 October 2027.

19:10 IST NSE
Regulatory ApprovalGrasim Industries Ltd GRASIM

Grasim Industries Regulatory Approval

CCI approved subsidiary ABReN's acquisition of 100% of Solenergi Power from Shell Overseas. The approval clears a regulatory condition for the deal announced on 13 July 2026.

08:07 IST BSE
Regulatory ApprovalHikal Ltd HIKAL

Hikal Regulatory Approval

Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.

08:05 IST BSE
Regulatory ApprovalSun Pharmaceutical Industries Ltd SUNPHARMA

Sun Pharmaceutical Industries Regulatory Approval

Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.

20:00 IST NSE
Regulatory ApprovalRNFI Services Ltd RNFI

RNFI Services Regulatory Approval

RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.